MapLight Therapeutics (MPLT) Current Deferred Revenue (2024 - 2025)
MapLight Therapeutics (MPLT) posted Current Deferred Revenue of $1.2 million for Q3 2025, down 62.5% sequentially from $3.2 million in Q4 2024.
MapLight Therapeutics (MPLT) Current Deferred Revenue (2024 - 2025) Analysis & Trends
MapLight Therapeutics has reported Current Deferred Revenue for 2 years, with the latest figure at $1.2 million in Q3 2025.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $1.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.2 million (changed N/A YoY) and the FY2024 annual result came in at $3.2 million, changed N/A from the prior year.
- Current Deferred Revenue eased to $1.2 million in Q3 2025 per MPLT's latest filing, from $3.2 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $3.2 million in Q4 2024 and troughed at $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.20 Mn |
| Dec 31, 2024 | 3.20 Mn |